These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35022752)

  • 21. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features.
    Seki M; Yabuno K; Miyawaki K; Miwa Y; Tomono K
    Clin Pharmacol; 2012; 4():71-5. PubMed ID: 23236257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China.
    Liu T; Wu J; Na P; Wu X; Yuan Y; Wang C; Ma X; Qi L; Chen X; Rao W; Duan Z; Fang X; Xie L; Li H
    BMC Geriatr; 2024 Jun; 24(1):487. PubMed ID: 38831261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interlaboratory analysis of teicoplanin plasma concentration assays among Chinese laboratories.
    Wang XX; Jin PF; Li PM; Xu S; Kong XD; Qin W; Chen WQ; Qin WJ; Zhang XL
    J Clin Pharm Ther; 2020 Oct; 45(5):983-990. PubMed ID: 31985852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity.
    Yamada T; Fujii S; Shigemi A; Takesue Y
    J Infect Chemother; 2021 Feb; 27(2):256-261. PubMed ID: 33077364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Level of evidence for therapeutic drug monitoring of teicoplatin].
    Boulamery A; Venisse N; Le Guellec C;
    Therapie; 2011; 66(1):45-50. PubMed ID: 21466777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.
    Choi JS; Kim JM; Kim D; Kim SH; Cho H; Park HD; Lee SY; Kang CI; Kim YJ
    J Korean Med Sci; 2020 Nov; 35(46):e376. PubMed ID: 33258328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-centre retrospective observational study comparing trough blood concentration and safety of teicoplanin formulations.
    Shinoda R; Shinoda Y; Ohashi K; Matsuoka T; Hirose T; Sugiyama T; Yoshimura T
    J Infect Chemother; 2019 Jul; 25(7):563-566. PubMed ID: 30929977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
    Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
    Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
    Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
    Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.
    Bel Kamel A; Bourguignon L; Marcos M; Ducher M; Goutelle S
    Ther Drug Monit; 2017 Feb; 39(1):83-87. PubMed ID: 27861313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use and therapeutic drug monitoring of teicoplanin in the UK.
    Darley ES; MacGowan AP
    Clin Microbiol Infect; 2004 Jan; 10(1):62-9. PubMed ID: 14706088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.